期刊文献+

局部晚期乳腺癌新辅助化疗剂量密集方案对比常规方案疗效与安全性的meta分析 被引量:3

Efficacy and safety of neoadjuvant chemotherapy dose-dense regimen versus conventional regimen for locally advanced breast cancer:a meta-analysis
原文传递
导出
摘要 目的系统评价局部晚期乳腺癌新辅助化学治疗(以下简称化疗)剂量密集方案对比常规方案的疗效与安全性。方法计算机检索PubMed、Embase、Web of Science、CNKI、WanFang Data和VIP数据库,搜集对比乳腺癌新辅助化疗剂量密集方案与常规方案的随机对照试验(randomized controlled trials,RCT),检索时限均为建库至2021年3月1日。由两名研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后采用Stata15.0软件进行meta分析。结果共纳入13个RCT,包括3258例患者,其中1625例患者接受了剂量密集新辅助化疗(dose-dense neoadjuvant chemotherapy,ddNACT),1633例患者接受了常规新辅助化疗(conventional neoadjuvant chemotherapy,cNACT)。meta分析结果显示:与cNACT组相比,ddNACT组的病理完全缓解率(P<0.001)、客观缓解率(P<0.001)和无病生存率(P=0.037)提高,2组总生存期(P=0.098)比较差异无统计学意义;ddNACT组3~4级口腔黏膜炎(P=0.005)和3~4级神经毒性(P<0.001)发生率均高于cNACT组,ddNACT组3~4级粒细胞减少发生率低于cNACT组(P=0.025),2组在3~4级血小板减少(P=0.152)、3~4级贫血(P=0.123)、化疗完成率(P=0.161)和保乳率(P=0.186)方面比较其差异均无统计学意义;激素受体阴性(hormone receptor negative,HR–)患者新辅助化疗后更易获病理完全缓解(P<0.001)。结论当前证据显示,在局部晚期乳腺癌患者中使用以蒽环类/紫杉类药物为基础的ddNACT方案较cNACT方案能提高病理完全缓解率、客观缓解率和无病生存率,HR–较HR+亚组新辅助化疗后病理完全缓解率更高,预防性使用粒细胞集落刺激因子能显著降低粒细胞减少的发生率,且大多数患者对剂量密集治疗是耐受的,两种化疗方案具有相似的完成率。 Objective To systematically evaluate the efficacy and safety of dose-dense neoadjuvant chemotherapy(ddNACT)and conventional neoadjuvant chemotherapy(cNACT)for locally advanced breast cancer(LABC).Methods PubMed,Embase,Web of Science,CNKI,Wanfang Data,and VIP databases were searched for randomized controlled trials(RCT)comparing ddNACT regimen with cNACT regimen for breast cancer.The time limit for retrieval was from establishment to March 1st,2021.Two reviewers independently screened literatures,extracted data and assessed risk bias of included studies;then,meta-analysis was performed by using Stata 15.0 software.Results A total of 13 RCTs were included,including 3258 patients,of which 1625 patients received ddNACT and 1633 patients received cNACT.The results of meta-analysis showed that the ddNACT regimen could improve the pathological complete response rate(pCR,P<0.001),objective response rate(ORR,P<0.001),and disease free survival(DFS,P=0.037)as compared with the cNACT regimen,there was no significant difference in the overall survival(OS)between the two groups(P=0.098).The incidences of grade 3 or 4 oral stomatitis(P=0.005)and neurotoxicity(P<0.001)were higher and the incidence of grade 3 or 4 neutropenia was lower(P=0.025)in the patients with ddNACT regimen,there were no significant differences in grade 3 or 4 thrombocytopenia(P=0.152),grade 3 or 4 anemia(P=0.123),chemotherapy completion rate(P=0.161)and breast conservative surgery rate(P=0.186)between the two groups.Patients with hormone receptor(HR)negative(HR–)were more likely to get pCR after neoadjuvant chemotherapy(P<0.001).Conclusions Current evidence shows that the use of anthracycline/taxane-based ddNACT regimen in LABC patients can improve the pCR,ORR,and DFS as compared with cNACT regimen.The pCR after neoadjuvant chemotherapy in the patients with HR–is higher than that with HR+.Prophylactic use of granulocyte-colony stimulating factor could significantly reduce the incidence of neutropenia,and most patients are tolerant to ddNACT regimen,2 re
作者 邓建 聂贤丽 胡莺菡 高旭东 陈进 权毅 DENG Jian;NIE Xianli;HU Yinghan;GAO Xudong;CHEN Jin;QUAN Yi(Department of Breast Surgery,Affiliated Hospital of Southwest Medical University,Luzhou,Sichuan 646000,P.R.China)
出处 《中国普外基础与临床杂志》 CAS 2022年第4期490-497,共8页 Chinese Journal of Bases and Clinics In General Surgery
基金 四川省科技厅专项资金计划项目(项目编号:14JC0197-LH38)。
关键词 乳腺癌 新辅助化学治疗 剂量密集方案 病理完全缓解 META分析 breast cancer neoadjuvant chemotherapy dose-dense regimen pathological complete response meta-analysis
  • 相关文献

参考文献6

二级参考文献38

  • 1陈丰,何向明,邹德宏.EC序贯P剂量密集方案与常规方案在乳腺癌新辅助化疗中的临床研究[J].中文科技期刊数据库(文摘版)医药卫生,2016(8):256-257. 被引量:1
  • 2聂建云,邹天宁,陈德滇,陈文林.新辅助化疗对乳腺癌TNM分期及术后治疗方案影响的研究[J].现代肿瘤医学,2006,14(2):161-162. 被引量:2
  • 3FORNIER M, NORTON L. Dose-dense adjuvant chemotherapy for primary breast cancer[J]. Breast Cancer Res,2005,7(2) :64-69. 被引量:1
  • 4CITRON M L, BERRY D A, CIRRINCIONE C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B Trial 9741 [J]. J Clin Oncol,2003, 21 (8) : 1431-1439. 被引量:1
  • 5HAMILTON A, HORTOBAGYI G. Chemotherapy: what progress in the last 5 years[J]? J Clin Oncol,2005, 23(8) :1760-1775. 被引量:1
  • 6DANG CT,D'ANDREA GM, MOYNAHAN ME, et al. Phase Ⅱ study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more nodepositive breast cancer [ J]. Clin Cancer Res,2004, 10(17) :5754-5761. 被引量:1
  • 7Citron ML, Berry DA, Cirrincione C. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Caneer and Leukemia Group B Trial 9741 [ J ] . J Clin Oneol, 2003, 21(8): 1431- 1439. 被引量:1
  • 8Hudis C. New approaches to adjuvant chemotherapy for breast cancer [ J ] . Phannacother, 1996, 16(3): 88-93. 被引量:1
  • 9Norton L, Simon R, Brereton HD, et al.Predicting the course of Gompertzian growth [ J ] . Nature, 1976, 264(5586): 542- 545. 被引量:1
  • 10Norton L. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy [ J ] . Oncologist, 2005, 10(6): 370-381. 被引量:1

共引文献20

同被引文献26

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部